Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib plus paclitaxel versus placebo plus paclitaxel in PIK3CA/AKT1/PTEN-altered advanced breast cancer
jRCT2080223714Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) and breast cancer comparing Ipatasertib + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Nov 2017; status: completed.
02
Drugs
ipatasertib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on jRCT2080223714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223714.